[Diagnostic-therapeutic trial in infantile genetic agranulocytosis with leucorecruitin].
Subject of this report is the usefulness of a biologically specific mediator of the leucocytosis reaction (leucorecruitin) in the diagnostic evaluation of granulopenic diseases. According to our trial the application of leucorecruitin in healthy humans resulted in a significant increase of granulocytes in circulating blood. The therapeutic effect depends on the neutrophil storage pool. In a diagnostic-therapeutic trial in infantile genetic agranulocytosis with depleted storage pools, leucorecruitin failed to lift the low number of circulating granulocytes to a normal level. No side effects could be observed so far.
D000380:Agranulocytosis / Q000175:diagnosis* / Q000235:genetics; D001853:Bone Marrow; D003937:Diagnosis, Differential; D006801:Humans; D007223:Infant; D007375:Interleukin-1; D007958:Leukocyte Count; D008297:Male; D011506:Proteins
D007375:Interleukin-1; D011506:Proteins; C008270:leukocyte endogenous mediator
Infantile genetische Agranulozytose (IGA). Leukorecrutin im diagnostisch-therapeutischen Versuch.